Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30281209 | 1.00 | L3MBTL1 (0.53) | L3MBTL1KDM4EALOX15TSHRACMSD | |
| SCHEMBL14152559 | 0.88 | CNR2 (0.58) | L3MBTL1KDM4EALOX15TSHRACMSD | |
| SCHEMBL30281288 | 0.86 | CNR2 (0.44) | L3MBTL1CNR2FFAR4POLBMAPK1 | |
| SCHEMBL2714731 | 0.86 | CNR2 (0.47) | L3MBTL1CNR2FFAR4POLBMAPK1 | |
| SCHEMBL18246933 | 0.83 | P2RX7 (0.61) | L3MBTL1KDM4ECNR2FFAR4POLB | |
| SCHEMBL27931901 | 0.83 | CNR2 (0.48) | L3MBTL1KDM4ECNR2FFAR4POLB | |
| SCHEMBL2717270 | 0.83 | MAPT (0.59) | L3MBTL1KDM4ETSHRCNR2MRGPRX4 | |
| SCHEMBL28130141 | 0.82 | CNR2 (0.59) | L3MBTL1CNR2KCNK3KCNK9MAPT | |
| SCHEMBL16731622 | 0.81 | L3MBTL1 (0.57) | L3MBTL1FFAR4POLBMAPK1EPHX2 | |
| SCHEMBL15940538 | 0.80 | KDM4E (0.57) | L3MBTL1KDM4EALOX15TSHRACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143195-B1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| EP-3487856-B1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | BAYER AG (DE) | 2025-01-22 | — | — | EP | disclosed |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-02 | — | — | US | disclosed |
| EP-4364798-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | Annapurna Bio Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11944622-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | ANNAPURNA BIO, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-3860998-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | SHOUTI INC. | 2023-06-01 | — | — | US | disclosed |
| WO-2013161308-A1 | AMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013161312-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2013-10-31 | — | — | WO | disclosed |
| EP-2630122-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2013-08-28 | — | — | EP | disclosed |
| CN-103249721-A | Arylamine Derivatives as TTX-S Blockers | RAQUALIA PHARMA INC | 2013-08-14 | — | — | CN | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| EP-1165501-A1 | ALKENYL- AND ALKYNYL-CONTAINING METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6197770-B1 | ENZYME INHIBITORS; ANTIARTHRITIC AGENTS; BONE DISORDERS | THE PROCTER & GAMBLE CO. | 2001-03-06 | — | — | US | disclosed |
| WO-2000051975-A1 | ALKENYL- AND ALKYNYL-CONTAINING METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | L3MBTL1 2415/4885KDM4E 2583/4885ALOX15 616/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | L3MBTL1 2415/4885KDM4E 2583/4885ALOX15 616/4885 |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | L3MBTL1 2415/4885KDM4E 2583/4885ALOX15 616/4885 |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | L3MBTL1 2415/4885KDM4E 2583/4885ALOX15 616/4885 |
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | APLNR, AGTR1, AGTR2 | L3MBTL1 3775/4885KDM4E 3721/4885ALOX15 2154/4885 |
| US-11944622-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | APLNR, AGTR1, AGTR2 | L3MBTL1 3775/4885KDM4E 3721/4885ALOX15 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.